Drug Trial Radar · NCT01607957
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
800
Actual
Start
Jun 17, 2012
Primary completion
Jan 31, 2014
Study completion May 23, 2016
Sponsor
- Lead sponsor
- Taiho Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 30, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.
Conditions
- Colorectal Cancer
Interventions
TAS-102Drug
35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
PlaceboDrug
Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Every 8 weeks, up to 12 months after the last participant was randomized or until the target number of events (deaths) was met, whichever was later. (Overall survival data was collected till 24 Jan 2014 which was date of observation of the 571st death)
Locations
115 sites in 13 countries. Site status is shown where the registry gives one.
Arizona Center for Cancer Care
Glendale, Arizona
California Cancer Associates for Research and Excellence
Fresno, California
Ronald H. Yanagihara, MD
Gilroy, California
LAC and USC Medical Center
Los Angeles, California
USC Norris Comprehensive Cancer Center
Los Angeles, California
Pacific Hematology Oncology Associates
San Francisco, California
San Jose Medical Group
San Jose, California
Coastal Integrative Cancer Care
San Luis Obispo, California
Yale Cancer Center
New Haven, Connecticut
MD Anderson Cancer Center Orlando
Orlando, Florida
Illinois Cancer Care, P.C.
Peoria, Illinois
Indiana University Simon Cancer Center
Indianapolis, Indiana
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana
Ochsner Clinic Fndtn
New Orleans, Louisiana
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
St. Joseph Mercy Hospital
Ann Arbor, Michigan
Jefferson City Medical Group
Jefferson City, Missouri
Saint Luke's Cancer Institute
Kansas City, Missouri
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
Gabrail Cancer Center
Canton, Ohio
Hickman Cancer Center at Flower Hospital
Sylvania, Ohio
Hematology/Oncology Associates of Fredericksburg
Fredericksburg, Virginia
Royal North Shore Hospital
Sydney, New South Wales, Australia
The Queen Elisabeth Hospital
Woodville South, South Australia, Australia
Austin Hospital
Heidelberg, Victoria, Australia
The Royal Melbourne Hospital
Parkville, Victoria, Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia
Krankenhaus der Barmherzigen Schwestern Linz
Linz, Austria
Universitaet Wien
Vienna, Austria
Universitaetsklinik fur Innere Medizin
Vienna, Austria
Wilhelminenspital Wien
Vienna, Austria
Klinikum Wels-Grieskirchen GmbH
Wels, Austria
Cliniques Universitaires UCL St. Luc
Brussels, Belgium
Erasme University Hospital-ULB-Brussels
Brussels, Belgium
Grand Hospital de Charleroi
Charleroi, Belgium
Antwerp University Hospital
Edegem, Belgium
University Hospital Gent
Edegem, Belgium
University Hospital Gent
Ghent, Belgium
Leuven University Hospital - Campus Gasthuiseberg
Leuven, Belgium
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.